Modafinil and Pseudotumor cerebri - a phase IV clinical study of FDA data

Summary:

Pseudotumor cerebri is reported as a side effect among people who take Modafinil (modafinil), especially for people who are female, 40-49 old, also take Xyrem, and have Cataplexy.

The phase IV clinical study analyzes which people have Pseudotumor cerebri when taking Modafinil. It is created by eHealthMe based on reports of 19,891 people who have side effects when taking Modafinil from the FDA, and is updated regularly.

What is Modafinil?

Modafinil has active ingredients of modafinil. It is often used in narcolepsy. eHealthMe is studying from 20,805 Modafinil users. Check the latest studies of Modafinil.

What is Pseudotumor cerebri?

Pseudotumor cerebri (increased pressure within the brain in the absence of a tumour) is found to be associated with 293 drugs and 929 conditions by eHealthMe. Check the latest studies of Pseudotumor cerebri.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

19,891 people reported to have side effects when taking Modafinil.
Among them, 15 people (0.08%) have Pseudotumor cerebri.

Could Modafinil cause Pseudotumor cerebri?

Among these 15 people:

What is the gender of people who have Pseudotumor cerebri when taking Modafinil? *

female: 93.33 %
male: 6.67 %

What is the age of people who have Pseudotumor cerebri when taking Modafinil? *

What are other drugs people take besides Modafinil? *

What are other side effects people have besides Pseudotumor cerebri? *

Weight Increased: 6 people, 40.00%
Migraine (headache): 6 people, 40.00%
Headache (pain in head): 5 people, 33.33%
Adverse Drug Reaction: 4 people, 26.67%
Paranasal Sinus Discomfort: 4 people, 26.67%
Nasopharyngitis (inflammation of the nasopharynx): 4 people, 26.67%
Meningitis (inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges): 3 people, 20.00%
Joint Pain: 3 people, 20.00%
High Blood Pressure: 3 people, 20.00%
Heart Palpitations (feelings or sensations that your heart is pounding or racing): 3 people, 20.00%

What are the existing conditions these people have? *

Cataplexy (loss of muscle tone accompanied by full conscious awareness): 11 people, 73.33%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 20.00%
Fatigue (feeling of tiredness): 2 people, 13.33%
Tension Headache: 1 person, 6.67%
Neuralgia (pain in one or more nerves): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Modafinil and have Pseudotumor cerebri?

- Check whether Pseudotumor cerebri is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Modafinil:

Modafinil (20,805 reports)

Browse all side effects of Modafinil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pseudotumor cerebri:

Pseudotumor cerebri (293 drugs)

Browse all the conditions that are associated with Pseudotumor cerebri:

Pseudotumor cerebri (929 conditions)

Related publications that referenced our studies

Lopes E, Pereira D, da Silva Behrens NS, de Almeida Fonseca H, Calvancanti PO, de Araújo Lima TF, Pradella-Hallinan M, Castro J, Tufik S, Coelho FM, "Cataplexy as a side effect of modafinil in a patient without narcolepsy", Sleep Science, 2014 Mar .
Lopes E, Pereira D, da Silva Behrens NS, de Almeida Fonseca H, Calvancanti PO, de Araújo Lima TF, Pradella-Hallinan M, Castro J, Tufik S, Coelho FM, "Cataplexy as a side effect of modafinil in a patient without narcolepsy", Sleep Science, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on modafinil (the active ingredients of Modafinil) and Modafinil (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.